Amgen drug cuts small cell lung cancer death risk by 40%

Amgen's Imdelltra demonstrated a 40% reduction in the risk of death compared to chemotherapy in small cell lung cancer patients whose disease progressed after initial chemotherapy, according to Phase 3 trial data presented at the American Society of Clinical Oncology's annual meeting. The trial, involving 509 patients, showed Imdelltra extended median overall survival to 13.6 months versus 8.3 months with chemotherapy, with a manageable safety profile and improvements in patient-reported outcomes; these results are intended to support the drug's accelerated FDA approval from last year.

Analysis

Amgen's Imdelltra has demonstrated compelling efficacy in its Phase 3 trial for small cell lung cancer (SCLC) patients whose disease progressed post-initial chemotherapy, significantly strengthening its clinical profile and market outlook. The 509-patient study showed Imdelltra reduced the risk of death by 40% and extended median overall survival to 13.6 months, a notable 5.3-month improvement over the 8.3 months observed with standard chemotherapy. Median progression-free survival also favored Imdelltra at 4.2 months versus 3.7 months for chemotherapy. These pivotal findings, presented at the American Society of Clinical Oncology's annual meeting and published in The New England Journal of Medicine, are intended to serve as confirmatory evidence supporting the conversion of Imdelltra's 2023 accelerated FDA approval to full approval for extensive-stage SCLC. SCLC, targeted by this bispecific antibody, represents up to 15% of lung cancer cases, indicating a significant patient population. Critically, Imdelltra exhibited a superior safety profile, with serious side effects reported in 27% of treated patients compared to 62% for chemotherapy, and manageable cytokine release syndrome, alongside improved patient-reported outcomes such as reduced cough and shortness of breath, further enhancing its therapeutic value.

Key Decisions for Investors

• The robust Phase 3 data for Imdelltra significantly bolsters Amgen's oncology portfolio and suggests a strong potential for market penetration in the challenging small cell lung cancer segment.
• Investors should monitor for the full FDA approval based on these confirmatory results, which would likely serve as a positive catalyst for AMGN and solidify Imdelltra's position as a new standard of care.
• The demonstrated improvements in overall survival and tolerability over chemotherapy position Imdelltra favorably, warranting an assessment of its impact on Amgen's future revenue growth and competitive standing in oncology.